AVCJ

Weekly digest - February 23 2022

Weekly digest - February 23 2022
  • LinkedIn  
  • Google plus  
  • Save this article  

23 February 2022
INFRASTRUCTURE: OUT OF THE COMFORT ZONE
COVER STORY
As infrastructure managers push into Australia's PE space, is the definition of core-plus being stretched too far?
GP PROFILE
SOUTHEAST ASIA'S CREADOR
SOUTHEAST ASIA'S CREADORCreador claims to be Southeast Asia's only middle-market GP with on-the-ground capacities across the region. But in-house post-deal support and nimble deal sourcing are its key differentiators.
DEAL FOCUS
SOBOT'S JOURNEY FROM UNDERDOG TO TOP DOG
SOBOT'S JOURNEY FROM UNDERDOG TO TOP DOGA USD 100m Series D confirmed Sobot's status as a leading player in China's customer service software space, but getting there has not been a straightforward process.
DEAL FOCUS
TAPPING A SOFT SPOT FOR ASIA VCs
TAPPING A SOFT SPOT FOR ASIA VCsInvestment professionals in Asia know on a personal level exactly what education technology provider Cialfo is doing and why the service is a big help. Now they're taking it to the next level.
DEAL FOCUS
FREIGHT PLAYER G7 EYES PUBLIC LISTING
FREIGHT PLAYER G7 EYES PUBLIC LISTINGHaving expanded its business scope from hardware into software and financial services, G7 Network is positioning its recent USD 200m PE investment as a pre-IPO round.
AVCJ AWARDS 2021
EXIT OF THE YEAR - LARGE CAP: SOFTEX INDONESIA
EXIT OF THE YEAR - LARGE CAP: SOFTEX INDONESIANCVC Capital Partners helped Softex Indonesia grow its market share by penetrating modern retail channels and launching an ESG program. A USD 1.2bn trade sale exit to Kimberly-Clark was its reward..
AVCJ AWARDS 2021
OPERATIONAL VALUE ADD: BEST & LESS GROUP
OPERATIONAL VALUE ADD: BEST & LESS GROUPAllegro Funds plucked Australian baby and kids retailer Best & Less from its underperforming parent and defied pandemic-related uncertainty to complete a turnaround that culminated in an IPO.
AVCJ AWARDS 2021
DEAL OF THE YEAR - LARGE CAP: CHINA BIOLOGIC
DEAL OF THE YEAR - LARGE CAP: CHINA BIOLOGICFor Centurium Capital, China Biologic was no ordinary take-private. It was the culmination of a multi-year effort to tighten the company's shareholding structure and root out management inefficiencies.
The rest of the week
FUNDS
DEALS
  • LinkedIn  
  • Google plus  
  • Save this article  

More on Region

Latest News

Asian GPs slow implementation of ESG policies - survey
Asian GPs slow implementation of ESG policies - survey

Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...

  • GPs